Follow Cidara Therapeutics, Inc. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.
2 Stories in coverage 0 Programs 32 recruiting Registered trials 10-Q Nov 4 Latest SEC filing Form DMay 6 $240M sold
Timeline 2 Pipeline 0 Trials 3
Details
Headquarters San Diego, CA Incorporated Delaware Industry Biological Products, (No Diagnostic Substances) Formerly K2 THERAPEUTICS, INC. (to 2015) How the company describes itself Cidara Therapeutics develops drug-Fc conjugates combining targeted small molecules or peptides with antibody fragments for immune-mediated disease clearance. Its lead candidate, CD388, is a long-acting antiviral for influenza prevention with Breakthrough Therapy Designation. Based in San Diego, California. source
